Skip to content
Biodatica
Start free

VELUM, INC.

CAMBRIDGE, MA

OncologyGrant-only
Compare Sign in to watch

What changed

NIH R42 · $1.0M · A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic Syndrome

10mo agoGrant renewalSep 12, 2025Source filing (opens the source filing in a new tab)

Momentum

38no change

Momentum 38 out of 100, unchanged since the last recompute.

Little recent filing activity, or the events on file have decayed.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    R41 · $315k · non-dilutive

    Sep 1, 2025

    VELUM, INC. · PI KUMAR, KRISHNA · NIDDK · award ends Aug 31, 2027 · Peptide YY triagonist weight loss drugs

    NIH RePORTER · NIH RePORTER 11256223 (opens the source filing in a new tab)

  2. Grant

    R42 · $959k · non-dilutive

    May 1, 2022

    VELUM, INC. · PI KUMAR, KRISHNA · NIDDK · award ends Apr 30, 2027 · A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic Syndrome

    NIH RePORTER · NIH RePORTER 11094854 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources